Format

Send to

Choose Destination
Expert Rev Proteomics. 2019 Apr;16(4):325-336. doi: 10.1080/14789450.2019.1592682. Epub 2019 Mar 22.

Protein biomarkers for cardiorenal syndrome.

Author information

1
a Biotechnology Division, Biomedical Research Foundation , Academy of Athens (BRFAA) , Athens , Greece.

Abstract

The term cardiorenal syndrome (CRS) describes the progressive pathology and interactions that develop upon heart and kidney failure. The definition of CRS is not firmly established and has evolved gradually during the last decade. The main clinical challenges associated with CRS are the lack of tools for early disease diagnosis and the inability to predict the development of cardiorenal pathophysiology. Currently several biomarkers have been proposed for improving CRS patient management. However, validation studies are needed to implement these initial findings to the clinical setting. Areas covered: In this review the database PubMed was used for a literature search on the definition and classification of CRS as well as biomarkers for CRS diagnosis and prognosis. Expert opinion: A universally acceptable classification system for CRS is not available. Thus, acquiring mechanistic insights relative to the pathophysiology of the disease is challenging. Reported biomarkers include well-established markers for heart/renal dysfunction and inflammation. Some proteins expressed in both organs have also been associated with CRS, yet their link to disease pathophysiology and organ cross-talk is missing. Establishing the link between deregulated molecular pathways and CRS phenotypes is required to define biological relevance of existing findings and ultimately biology-driven markers and targets.

KEYWORDS:

Cardiorenal syndrome; acute kidney injury; cardiac and renal biomarkers; cardiorenal biomarkers; chronic kidney disease; heart failure

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center